Sep 13, 2022 / 09:15PM GMT
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity Analyst
All right, thanks, everyone, for joining us today. I'm Drew Ranieri, a member of the medtech team here. It's my pleasure to have Curt Hartman and Todd Garner, the CEO and CFO of CONMED. Before we kind of jump into Q&A, just our quick disclaimer, but for important disclosures, please see Morgan Stanley Research disclosure's website. And if you have any questions, just reach out to your Morgan Stanley sales rep.
Questions and Answers:
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity AnalystBut again, pleasure Curt and Todd to have you with us today. And we kind of started some of these conversations really kind of on the macro standpoint. And just as we've kind of heard through the past couple of days and even last week, it sounds like from a procedure volume perspective that things have slowed down in June, July and then improved in August and even into September. But we would kind of love to hear your views on that from a sports medicines perspective